Search Results
Results found for "Jan Voss"
- Use of CRISPR/Cas9-edited HEK293 cells reveals that both conventional and novel protein kinase C...
Nonetheless, we determined that mGlu5a internalization was not altered upon the loss of cPKCs or nPKCs
- Enhanced membrane binding of oncogenic G protein αqQ209L confers resistance to inhibitor YM-254890
To test if this loss of PM localization could contribute to the mechanism of inhibition of αqQ209L by
- GPR3 expression in retinal ganglion cells contributes to neuron survival and accelerates axonal...
The axonal degeneration that occurs before retinal ganglion neuronal loss is suggested to be involved
- Coordinated transcriptomics and peptidomics of central nervous system identify neuropeptides and ...
oriental fruit moth Grapholita molesta is a cosmopolitan pest of orchard, which causes serious economic losses
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
The takeaway is clear: fast clearance does not necessarily mean loss of efficacy when binding offset
- Molecular creativity in drug discovery
Breakthroughs this week: Orphan receptor GPRC5B in neurogenesis; Septerna’s pill-based weight-loss strategy
- 🎄 Have Yourself a Merry Little GPCRmas! ❄ Dec 9 - 15, 2024
discoveries could revolutionise women’s health Seven unanswered questions about blockbuster weight-loss
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
DR curves shift to the right with no loss of maximal effect.
- 📰 GPCR Weekly News, October 2 to 8, 2023
novel fluorescent Endothelin-B receptor probes GPCRs in Cardiology, Endocrinology, and Taste GPRASP1 loss-of-function
- Phenylalanine 193 in Extracellular Loop 2 of the β 2-Adrenergic Receptor Coordinates β-Arrestin ...
loop 2 in the β2-adrenergic receptor mediates interactions with G protein and β-arrestin with a biased loss
- How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs
Build theories, but be ready to toss them.
- Feeder or trigger – CCR2 as a scavenger and regulator of cell migration
was significantly diminished iin Gαi KO and Gα_all KO HEK293 cells, however there was only a minor loss HEK293 cells with CRISPR KO of both β-arrestin1 and β-arrestin2 only led to a small but measurable loss
- 📰 GPCR Weekly News, October 9 to 15, 2023
analysis Reviews, GPCRs, and more Parallel evolution of the G protein-coupled receptor GrlG and the loss
- 📰 GPCR Weekly News, October 23 to 29, 2023
Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress Parker Moss
- 📰 GPCR Weekly News, June 19 to 25, 2023
Industry News Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim
- 📰 GPCR Weekly News, April 1 to 7, 2024
dive into the Classified GPCR News from April 1st to 7th, 2024 GPCR Activation and Signaling GPRASP1 loss-of-function
- Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success
Months of wasted resources, failed translation, and opportunity loss.
- 📰 GPCR Weekly News, June 5 to 11, 2023
Ines Liebscher, Ross Cheloha and Silvio Gutkind.
- 📰 GPCR Weekly News, March 20 to 26, 2023
Loss of biased signaling at a G protein-coupled receptor in overexpressed systems.
- Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024
Postdoc in GPCR mechanosensing Postdoctoral Position Postdoctoral research position Adhesion GPCRs Loss
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
Rodriguez, P.J., et al., Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
- Unlocking the Future of Medicine: Advancements in GPCR Research
activation RhoA-mediated G12-G13 signaling maintains muscle stem cell quiescence and prevents stem cell loss
- 📰 GPCR Weekly News, May 27 to June 2, 2024
Canonical chemokine receptors as scavenging “decoys” Shivani Sachdev, Brendan Creemer, Thomas Gardella, and Ross
- 📰 GPCR Weekly News, February 20 to 26, 2023
Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss
- Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence
droplets; novel atypical GPCR-arrestin complexes; Lilly's oral GLP-1, orforglipron, delivers weight loss
- 📰 GPCR Weekly News, February 12 to 18, 2024
Nayara Braga Emidio, Ross Cheloha, Laura M Wingler, et al. for their work on Nanobody-Mediated Dualsteric
- 📰 GPCR Weekly News, July 1 to 7, 2024
Ross Bathgate, Francisco Olucha-Bordonau, et al.
- 📰 GPCR Weekly News, December 11 to 17, 2023
Ross Cheloha's research involves semi-synthetic nanobody-ligand conjugates with enhanced transcriptional
- 📰 GPCR Weekly News, January 29 to February 4, 2024
Structural and functional insight into the interaction of Clostridioides difficile toxin B and FZD7 Loss-of-function
- Hop in the Time Machine with GPCR: Unraveling the Future of Research! ⦿ Nov 24 - Dec 1, 2024
from November 25th to December 1st, 2024 Industry News Amgen says obesity drug caused up to 20% weight loss











